Статья
КАТЕСТАТИН КАК НОВЫЙ МАРКЕР СЕРДЕЧНО-СОСУДИСТОГО РИСКА У БОЛЬНЫХ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ
Обзор ключевых исследований по изучению антигипертензивного, вазодилататорного, ангиогенного и анти-апоптотического действия катестатина — пептида, образующегося в результате взаимодействия эндогенных протеаз с С-концом хромогранина А. Плазменные уровни катестатина обратно коррелируют с фенотипом артериальной гипертензии, особенно на ранних стадиях развития гипертонической болезни. Обсуждается патогенетическая роль катестатина в развитии гипертонической болезни и его возможное использование в качестве маркера стратификации сердечно-сосудистого риска.
1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul; 31 (7): 1281-357. DOI: 10.1097/01.hjh.0000431740.32696.cc.
2. Mancia G, Laurent S, Agabiti-Rosei E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009 Nov; 27 (11): 2121-58. DOI: 10.1097/HJH.0b013e328333146d.
3. Boitsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among persons 25-64 years of age: prevalence, awareness, treatment and control. According to the ESSAY study. Cardiovascular Therapy and Prevention 2014; 13 (4): 4-14. (In Russ.) Бойцов C. A., Баланова Ю. А., Шальнова С. А. и др. Артериальная гипертензия среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика 2014. 13 (4): 4-14. DOI:10.15829/1728-8800-2014-4-4-14.
4. Kobalava ZhD, Kotovskaya YuV, Moiseev VS. Arterial hypertension. The keys for diagnostics and treatment. M.; GEOTAR-Media, 2009. p. 38. (In Russ) Кобалава Ж. Д., Котовская Ю. В., Моисеев В. С. Артериальная гипертония. Ключи к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009 p. 38.
5. Haq IU, Ramsay LE, Yeo WW, et al. Is the Framingham risk unction valid for northern European populations? A comparison of methods for estimating absolute coronaryrisk in high risk men. Heart 1999; 81 (1): 40-6.
6. Conroy RM, Fitzgelald AP, Graham IM, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal 2003; 24 (11): 987-1003.
7. Troger J, Theurl M, Kirchmair R, et al. Granin-derived peptides. Prog Neurobiol. 2017 Jul; 154: 37-61. DOI: 10.1016/j.pneurobio.2017.04.003.
8. Zhao Y, Zhu D. Potential applications of catestatin in cardiovascular diseases. Biomark Med. 2016 Aug; 10 (8): 877-88. DOI: 10.2217/bmm-2016-0086.
9. Gaede AH, Pilowsky PM. Catestatin in rat RVLM is sympathoexcitatory, increases barosensitivity, and attenuates chemosensitivity and the somatosympathetic reflex. Am J Physiol Regul Integr Comp Physiol. 2010 Dec; 299 (6): R1538-45. DOI: 10.1152/ajpregu.00335.2010.
10. Biswas N, Curello E, O’Connor DT, et al. Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga (364-384)). Cell Tissue Res 2010; 342 (3): 353-61. DOI: 10.1007/s00441-010-1059-4.
11. D’amico MA, Ghinassi B, Izzicupo P, et al. Biological function and clinical relevance of chromogranin A and derived peptides. Endocr Connect. 2014 Apr 29; 3 (2): R45-54. DOI: 10.1530/EC-14-0027.
12. Kiranmayi M, Chirasani VR, Allu PK, et al. Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway. Hypertension 2016 Aug; 68 (2): 334-47. DOI: 10.1161/HYPERTENSIONAHA.116.06568.
13. Choi Y, Miura M, Nakata Y, et al. A common genetic variant of the chromogranin A-derived peptide catestatin is associated with atherogenesis and hypertension in a Japanese population. Endocr J. 2015; 62 (9): 797-804. DOI: 10.1507/endocrj.EJ14-0471.
14. Mazza R, Gattuso A, Mannarino C, et al. Catestatin (chromogranin A344–364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart. Am J Physiol Heart Circ Physiol. 2008 Jul; 295 (1): H113-22. DOI: 10.1152/ajpheart.00172.2008.
15. Angelone T, Quintieri AM, Brar BK, et al. The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology 2008 Oct; 149 (10): 4780-93. DOI: 10.1210/en.2008-0318.
16. Angelone T, Quintieri AM, Pasqua T, et al. The NO stimulator, Catestatin, improves the Frank-Starling response in normotensive and hypertensive rat hearts. Nitric Oxide 2015 Aug 1; 50: 10-9. DOI: 10.1016/j.niox.2015.07.004.
17. Avolio E, Mahata SK, Mantuano E, et al. Antihypertensive and neuroprotective effects of catestatin in spontaneously hypertensive rats: interaction with GABAergic transmission in amygdala and brainstem. Neuroscience 2014 Jun 13; 270: 48-57. DOI: 10.1016/j. neuroscience.2014.04.001.
18. Mahata S, Kiranmayi M, Mahapatra NR. Catestatin: a master regulator of cardiovascular functions. Curr Med Chem. 2017 Apr 24. DOI: 10.2174/0929867324666170425100416.
19. Bassino E, Fornero S, Gallo MP, et al. A novel catestatin induced antiadrenergic mechanism triggered by the endothelial PI3K–eNOS pathway in the myocardium. Cardiovasc Res. 2011 Sep 1; 91 (4): 617-24. DOI: 10.1093/cvr/cvr129.
20. Kojima M, Ozawa N, Mori Y, et al. Catestatin Prevents Macrophage-Driven Atherosclerosis but Not Arterial Injury-Induced Neointimal Hyperplasia. Thromb Haemost. 2018 Jan; 118 (1): 182-94. DOI: 10.1160/TH17-05-0349.
21. Rabbi MF, Eissa N, Munyaka PM, et al. Reactivation of intestinal inflammation is suppressed by catestatin in a murine model of colitis via M1 macrophages and not the gut microbiota. Front Immunol 2017; 8: 985. DOI: 10.3389/fimmu.2017.00985.
22. Liu R, Sun NL, Yang SN, et al. Catestatin could ameliorate proliferating changes of target organs in spontaneously hypertensive rats. Chin Med J (Engl) 2013; 126 (11): 2157-62. DOI: 10.1097/01.hjh.0000420143.10024.6a.
23. Brar BK, Helgeland E, Mahata SK, et al. Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. Regul Pept. 2010 Nov 30; 165 (1): 63-70. DOI: 10.1016/j.regpep.2010.07.153.
24. Penna C, Alloatti G, Gallo MP, et al. Catestatin improves postischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol Neurobiol. 2010 Nov; 30 (8): 1171-9. DOI: 10.1007/s10571-010-9598-5.
25. Theurl M, Schgoer W, Albrecht K, et al. The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res. 2010 Nov 26; 107 (11): 1326-35. DOI: 10.1161/CIRCRESAHA.110.219493.
26. Guo X, Zhou C, Sun N. The neuropeptide catestatin promotes vascular smooth muscle cell proliferation through the Ca2þ calcineurin-NFAT signaling pathway. Biochem Biophys Res Commun 2011; 407 (04): 807-12.
27. Mahapatra NR, O’Connor DT, Vaingankar SM, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005; 115: 1942-52. DOI: 10.1172/JCI24354.
28. Rao F, Wen G, Gayen JR, et al. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352–372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 2007 May 1; 115 (17): 2271-81. DOI: 10.1161/CIRCULATIONAHA.106.628859.
29. O’Connor DT, Zhu G, Rao F, et al. Heritability and Genome-Wide Linkage in US and Australian Twins Identify Novel Genomic Regions Controlling Chromogranin A: Implications for Secretion and Blood Pressure. Circulation 2008 Jul 15; 118 (3): 247-57. DOI: 10.1161/ CIRCULATIONAHA.107.709105.
30. Saiful A. Mir, Kuixing Zhang, Milos Milic, et al. Analysis and validation of traits associated with a single nucleotide polymorphism Gly364Ser in catestatin using humanized chromogranin A mouse models. J Hypertens. 2016 Jan; 34 (1): 68-78. DOI: 10.1097/HJH.0000000000000760.
31. O’Connor DT, Kailasam MT, Kennedy BP, et al. Early decline in the catecholamine releaseinhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens. 2002 Jul; 20 (7): 1335-45.
32. Sahu BS, Mohan J, Sahu G, et al. Molecular interactions of the physiological antihypertensive peptide catestatin with the neuronal nicotinic acetylcholine receptor. J Cell Sci. 2012 May 1; 125 (Pt 9): 2323-37. DOI: 10.1242/jcs.103176.
33. Durakoglugil ME, Ayaz T, Kocaman SA, et al. The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. Anatol. J. Cardiol. 2015; 15 (7): 577-85. DOI: 10.5152/akd.2014.5536.
34. Bandyopadhyay GK, Vu UC, Gentile S, et al. Catestatin (Chromogranin A352-372) and Novel Effects on Mobilization of Fat from Adipose Tissue through Regulation of Adrenergic and Leptin Signaling. J Biol Chem. 2012 Jun 29; 287 (27): 23141-51. DOI: 10.1074/jbc.M111.335877.
35. Sahu BS, Obbineni JM, Sahu G, et al. Functional genetic variants of the catecholaminerelease-inhibitory peptide catestatin in an Indian population: allele-specific effects on metabolic traits. Biol Chem. 2012 Dec 21; 287 (52): 43840-52. DOI: 10.1074/jbc.M112.407916.
36. Meng L, Ye XJ, Ding WH, et al. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med (Hagerstown) 2011 Sep; 12 (9): 643-47. DOI: 10.2459/JCM.0b013e328346c142.
37. Vaingankar SM, Li Y, Biswas N, et al. Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J Hypertens. 2010 Apr; 28 (4): 817-25. DOI: 10.1097/HJH.0b013e328336ed3e.
38. Schillaci G, De Vuono S, Pucci G. An endogenous brake on the sympathetic nervous system: the emerging role of catestatin in hypertension. J Cardiovasc Med (Hagerstown) 2011 Sep; 12 (9): 609-12. DOI: 10.2459/JCM.0b013e328348d925.
39. Salem RM, Cadman PE, Chen Y, et al. Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol. 2008 Mar; 19 (3): 600-14. DOI: 10.1681/ASN.2007070754.
40. Sun H, Xian W, Geng L, et al. Increased plasma level of catestatin might be associated with poor prognosis in hemodialysis patients. Int Urol Nephrol. 2017 Jun; 49 (6): 1063-9. DOI: 10.1007/s11255-017-1528-8.
41. Xu W, Yu H, Li W, et al. Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia. PLoS One. 2016 Jun 15; 11 (6): e0149062. DOI: 10.1371/journal.pone.0149062.
42. Xu W, Yu H, Wu H, et al. Plasma Catestatin in Patients with Acute Coronary Syndrome. Cardiology 2017; 136 (3): 164-9. DOI: 10.1159/000448987.
43. Wang X, Xu S, Liang Y, et al. Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction. Biomarkers 2011 Jun; 16 (4): 372-7. DOI: 10.3109/1354750X.2011.578260.
44. Meng L, Wang J, Ding WH, et al. Plasma catestatin level in patients with acute myocardial infarction and its correlation with ventricular remodelling. Postgrad. Med. J. 2013; 89 (1050): 193-6. DOI: 10.1136/postgradmedj-2012-131060.
45. Pei Z, Ma D, Ji L, et al. Usefulness of catestatin to predict malignant arrhythmia in patients with acute myocardial infarction. Peptides. 2014 May; 55: 131-5. DOI: 10.1016/j. peptides.2014.02.016.
46. Liu L, Ding W, Li R, et al. Plasma levels and diagnostic value of catestatin in patients with heart failure. Peptides 2013 Aug; 46: 20-5. DOI: 10.1016/j.peptides.2013.05.003.
47. Zhu D, Wang F, Yu H, et al. Catestatin is useful in detecting patients with stage B heart failure. Biomarkers 2011; 16 (8): 691-7. DOI: 10.3109/1354750X.2011.629058.
48. Peng F, Chu S, Ding W, et al. The predictive value of plasma catestatin for all-cause and cardiac deaths in chronic heart failure patients. Peptides 2016 Dec; 86: 112-7. DOI: 10.1016/j.peptides.2016.10.007.